MAPT and Alzheimer disease: As a first step in confirming the AD-related tau phenotype and neuron differentiation of sAD2.1 iPSNs, we performed double immunofluorescence analysis for AT8 or AT180 tau and βIII-tubulin positive cells within sAD2.1 and AX0018 iPSNs (Fig. 3a, b).